Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension

Journal of Ocular Pharmacology and Therapeutics

Volumn 16, Issue 3, 2000, Pages 203-216

  Lacheretz, Frederic ^a   Barbier, Alain ^a   Serradeil Le Gal, Claudine ^a   Elena, Pierre Paul ^b   Maffrand, Jean Pierre ^a   Le Fur, Gerard ^a  

^a SANOFI   (France)

^b Iris Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; INTRAOCULAR HYPERTENSION; MALE; NONHUMAN; RABBIT; RECEPTOR AFFINITY;

EID: 0034122272     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2000.16.203     Document Type: Article

References (51)

1. Anderson, D.R. The management of elevated intraocular pressure with normal optic disks and visual fields: therapeutic approach based on high risk factors. Surv. Ophthalmol. 21:479-489, 1977.
2. Everitt, D.E. and Avorn, J. Systemic effects of medications used to treat glaucoma. Ann. Intern. Med. 112:120-125, 1990.
3. Tucker, J.B. Screening for open-angle glaucoma. Am. Fam. Physician 48:75-80, 1993.
4. Bill, A. and Phillips, I. Uveoscleral drainage of aqueous humor in human eyes. Exp. Eye Res. 12:275-281, 1971.
5. Bill, A. Conventional and uveoscleral drainage of aqueous humor in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp. Eye Res. 3:45-54, 1966.
6. Hoskins, H.D. and Kass, M. In Becker-Shaffer's Diagnosis and Therapy of the Glaucomas, 6th ed., C.V. Mosby, St Louis, 1989, pp. 2-9.
7. Dielemans, I., Vingerling, J.R., Algra, D., Hofman, A., Grobbee, D.E., and de Jong, P.V.T.M. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. Ophthalmology 102:54-60, 1995.
8. Chandler, P.A. and Grant, W.M. Diagnosis and treatment of glaucomas in adults. In Glaucoma, Epstein, D.L., ed., Lea and Febiger, Philadelphia, 1986, pp. 129-180.
9. Cole, D.F. Secretion of the aqueous humor. Exp. Eye Res. 25:161-176, 1977.
10. Kaufman, P.L. and Barany, E.H. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest. Ophthalmol. 15:793-807, 1976.
11. Zimmerman, T.J. Pilocarpine. Ophthalmology 88:85-88, 1981.
12. Nilsson, S.F.E., Samuelsson, M., Bill, A., and Stjernschantz, J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48:707-716, 1989.
13. Toris, C.B., Camras, C.B., and Yablonski, M.E. Effects of PhXA41, a new prostaglandin F2 analog on aqueous humor dynamics in human eyes. Ophthalmology 100:1297-1304, 1993.
14. Zimmerman, T.J. Mechanism of action of topical epinephrine. Ann. Ophthalmol. 16:307-308, 1984.
15. Boger, W.P. Short-term escape and long-term drift. The dissipation effects of the beta-adrenergic blocking agents. Surv. Ophthalmol. 28:235-240, 1983.
16. Johnson, D.H., Kenyon, K.R., Epstein, D.L., and Van Buskirk, E.M. Corneal changes during pilocarpine gel therapy. Am. J. Ophthalmol. 101:13-15, 1986.
17. Blanchard, D.L. Adrenergic-associated symblepharon. Glaucoma 9:18-20, 1987.
18. Kalina, P.H., Shetler, D.J., Lewis, R.A., Kullerstrand, L.J., and Brubaker, R.F. 6-amino-2-benzothiazole-sulfonamide, the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology 95:772-777, 1988.
19. Alm, A. and Stjernschantz, J. The Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening or morning. A comparison with timolol. Ophthalmology 102:1743-1752, 1995.
20. Diggory, P. and Frank, W. Glaucoma: systemic side-effects of topical medical therapy-a common and recognized problem. J. R. Soc. Med. 87:575-576, 1994.
21. Everitt, D.E. and Avom, J. Systemic effects of medications used to treat glaucoma. Ann. Intern. Med. 112:120-125, 1990.
22. Epstein, D.L. and Grant, W.M. Carbonic anhydrase inhibitor side-effects. Arch. Ophthalmol. 95:1378-1382, 1977.
23. 2 receptor antagonist. J. Clin. Invest. 98:2729-2738, 1996.
24. Too, H.P., Todd, K., Lightman, S.L., Horn, A., Unger, W.G., and Hanley, M.R. Presence and actions of vasopressin-like peptides in the rabbit anterior uvea. Regul. Pept. 25:259-266, 1989.
25. Allison, N.L., Albrightson-Winslow, C.R., Brooks, D.P., Stassen, F.L., Huffman, W.F., Stote, R.M., and Kinter, L.B. Species heterogeneity and antidiuretic hormone antagonists : what are the predictors? In Vasopressin: Cellular and Integrative Functions, Allen, W., Cowley, J.R., Liard, J.F, and Ausiello, D.A., eds., Raven Press, New York, 1988, pp. 207-214.
26. Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J.P., Le Fur, G., Guillon, G., Cantau, B., Barberis, C., Trueba, M., Ala, Y., and Jard, S. Biochemical and pharmacological properties of SR49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 92:224-231, 1993.
27. Stassen, F.L., Erickson, R.W., Huffman, W.F., Stefankiewicz, J., Sulat, L., and Wiebelhaus, V.D. Molecular mechanisms of novel antidiuretic antagonist: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J. Pharmacol. Exp. Ther. 223:50-54, 1982.
28. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254, 1976.
29. 2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. 282:597-602, 1997.
30. Munson, P.V. and Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:220-239, 1980.
31. Cheng, Y. and Prusoff, W. Relationship between the inhibition constant (Ki) and the concentration of inhibition which cause 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108, 1973.
32. Himber, J., De Burlet, G., and Andermann, G. Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: A comparative study. J. Ocul. Pharmacol. 5:93-98, 1989.
33. Chiang, C.H., Ho, J.I., and Chen, J.L. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. J. Ocul. Pharmacol. Ther. 12:471-480, 1996.
34. Amstrong, T.A. Evaluation of the Tonopen and the Pulsair tonometers. Am. J. Ophthalmol. 109:716-720, 1990.
35. Schwartz, J., Derdowska, I., Sobocinska, M., and Kypryzewski, G. A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary. Endocrinology 129:1107-1109, 1991.
36. Niederer, W., Richardson, B.P., and Donatsch, P. Hormonal control of aqueous humor production. Exp. Eye Res. 20:329-340, 1975.
37. Palm, D.E., Shue, S.G., Keil, L.C., Balaban, C.D., and Severs, W.B. Effects of angiotensin, vasopressin and atrial natriuretic peptide on intraocular pressure in anesthetized rats. Neuropeptides 29:193-203, 1995.
38. Balaban, C.D., Palm, D.E., Shikher, V., Searles, R.V., Keil, L.C., and Severs, W.B. Mechanisms for vasopressin effects on intraocular pressure in anesthetized rats. Exp. Eye Res. 65:517-531, 1997.
39. Cole, D.F. and Nagasubramanian, S. Substances affecting active transport across the ciliary epithelium and their possible role in determining intraocular pressure. Exp. Eye Res. 16:251-264, 1973.
40. Krupin, T., Webb, G.W., Barbosa, A.T., Gulli, B., Levine, J., and Becker, B. Central effects of thyrotropin-releasing hormone and arginine vasopressin on intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci. 25:932-937, 1984.
41. Cole, D.F. and Nagasubramanian, S. The effect of natural and synthetic vasopressin and other substances on active transport in ciliary epithelium of the rabbit. Exp. Eye Res. 13:45-57, 1972.
42. Nagasubramanian, S. The effect of vasopressin on the facility of aqueous humor outflow in the rabbit. Ophthalmol. Res. 6:301-307, 1974.
43. Friedman, Z., Delahunty, T.M., Linden, J., and Campochiaro, P.A. Human retinal pigment epithelial cells possess V1 vasopressin receptors. Curr. Eye Res. 10:811-816, 1991.
44. Searles, R.V., Balaban, C.D., and Severs, W.B. Interaction between head-down tilt and anterior chamber infusions on intraocular pressure of anesthetized rats. Exp. Eye Res. 62:621-626, 1996.
45. Okamura, T., Toda, M., Ayajiki, K., and Toda, N. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J. Vascul. Res. 34:464-472, 1997.
46. Patil, R.V., Saito, I., Yang, X., and Wax, M.B. Expression of aquaporins in the rat ocular tissue. Exp. Eye Res. 64:203-209, 1997.
47. Stamer, W.D., Snyder, R.W., Smith, B.L., Agre, P., and Regan, J.W. Localization of aquaporin CHIP in the human eye: implications in the pathogenesis of glaucoma and other disorders of ocular fluid balance. Invest. Ophthalmol. Vis. Sci. 35:3867-3872, 1994.
48. Ohara, M., Martin, P.Y., Xu, D.L., St John, J., Pattison, T.A., Kim, J.K., and Schrier, R.W. Upregulation of aquaporin-2 water channel expression in pregnant rats. J. Clin. Invest. 101:1076-1083, 1998.
49. Hayashi, M., Sasaki, S., Tsuganezawa, H., Monkawa, T., Kitajima, W., Konishi, K., Fushimi, K., Marumo, F., and Saruta, T. Role of vasopressin V2 receptor in acute regulation of aquaporin-2. Kidney Blood Press. Res. 19:32-37, 1996.
50. Jenq, W., Mathieson, I.M., Ihara, W., and Ramirez, G. Aquaporin-1: an osmoinducible water channel in cultured mIMCD-3 cells. Biochem. Biophys. Res. Commun. 245:804-809, 1998.
51. Patil, R.V., Han, Z., and Wax, M.B. Regulation of water channel activity of aquaporin-1 by arginine vasopressin and atrial natriuretic peptide. Biochem. Biophys. Res. Commun. 238:392-396, 1997.